Thompson Davis & Co., Inc. Mirati Therapeutics, Inc. Transaction History

Thompson Davis & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $115,508 - $166,503	-875 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $17,662 - $23,512	-375 Reduced 30.0%	875 $41,000
Q1 2018 May 02, 2018	SELL	$17.2 - $34.95 $4,300 - $8,737	-250 Reduced 16.67%	1,250 $38,000
Q4 2017 Feb 05, 2018	BUY	$12.65 - $19.0 $12,650 - $19,000	1,000 Added 200.0%	1,500 $27,000
Q3 2017 Oct 30, 2017	BUY	$4.7 - $11.7 $2,350 - $5,850	500	500 $6,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Thompson Davis & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on Thompson Davis & Co., Inc. with notifications on news.